As CEO of Portage Biotech, a clinical-stage company, Walters and his team are following a potentially disruptive scientific path to advance first-in-class immunotherapies that elevate or initiate the immune response across a range of cancer types.

Kathy Lee-Sepsick, the founder of Femasys, is determined to change the game in long-neglected areas of women’s healthcare, some of which haven’t had much innovation in more than a century.

A Navy veteran, former marathon runner, and father from Florida is riding to raise money for a deadly condition. He founded the group 20 years ago after his 23 year old daughter tragically died from sepsis. Carl Flatley traveled more than 200 miles and raised $35,000 last year. This year he has bigger goals.

Cell therapy is coming into its own as an effective therapeutic avenue for cancer. Into that fray in November 2019 launched Umoja Biopharma, whose unique immunotherapy approach aims to re-engineer a patient’s own immune system in vivo to attack and destroy hematologic and solid organ-based tumors.

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Recent years have seen a surge of research into rarer forms of kidney disease, with drug companies, regulators, and researchers alike hunting for ways to help patients who have few options.